Psoriasis is a systemic inflammatory chronic disease with increasing morbidity worldwide. Psoriasis is associated with many comorbidities such as diabetes and obesity. In the last years, treatment options have been based on biologic therapies to reduce symptoms, improve quality of life and reduce disease progression. Biologic drugs have played a major role in reducing the management and complications costs in psoriasis therapy. The goal of this study was to evaluate the costs-effectiveness of three psoriasis biologic therapies used in a large general hospital in Ecuador..
